Table 1.
Baseline characteristics of the patients who received either a low-dose 3-month DLI or 6-month DLI as first DLI.
| Low-dose 3-month DLI (N = 88) |
6-month DLI (N = 76) |
|
|---|---|---|
| Age at alloSCT (years) | ||
| median (range) | 58 (18–74) | 57 (19-76) |
| Disease | ||
| AML | 59 (67%) | 56 (74%) |
| ALL | 23 (26%) | 9 (12%) |
| MDS | 6 (7%) | 11 (14%) |
| Conditioning | ||
| MAC: Cyclo/TBI | 35 (40%) | 33 (43%) |
| MAC: Cyclo/Bu | 1 (1%) | 1 (1%) |
| RIC: Flu/Bu* | 38 (43%) | 42 (55%) |
| RIC: Flu/Bu/Ara-C/Amsa | 14 (16%) | 0 |
| Donor | ||
| RD | 39 (44%) | 30 (39%) |
| UD | 49 (56%) | 46 (61%) |
| Graft source | ||
| G-CSF mobilized PBSC | 84 (95%) | 70 (92%) |
| BM | 4 (5%) | 6 (8%) |
| CMV serostatus patient/donor | ||
| +/+ | 43 (49%) | 33 (43%) |
| +/- | 13 (15%) | 12 (16%) |
| -/+ | 6 (7%) | 4 (5%) |
| -/- | 26 (30%) | 27 (36%) |
| EBV serostatus patient/donor | ||
| +/+ | 78 (89%) | 59 (78%) |
| +/- | 6 (7%) | 7 (9%) |
| +/unknown | 0 | 4 (5%) |
| -/+ | 3 (3%) | 6 (8%) |
| -/- | 1 (1%) | 0 |
| Main indication of first DLI | ||
| ALL: t(9;22) | 11 (12%) | – |
| ALL: hypodiploidy, complex karyotype, or t(4;11) | 3 (3%) | – |
| ALL: high white blood cell count at diagnosis | 4 (5%) | – |
| ALL: no CR1 | 2 (2%) | – |
| AML: monosomal karyotype | 10 (11%) | – |
| AML: complex karyotype | 1 (1%) | |
| AML/MDS: EV1 overexpression | 15 (17%) | – |
| AML: ASXL mutation | 2 (2%) | |
| AML: FLT3 mutation | 1 (1%) | – |
| AML/MDS: FLAMSA regimen | 14 (16%) | |
| AML: progression during remission-induction | 1 (1%) | – |
| AML/MDS: no intensive treatment or no consolidation | 4 (5%) | – |
| AML/MDS: persisting CMML | 1 (1%) | – |
| MRD+ at time of alloSCT | 11 (12%) | – |
| Pre-emptive for MC | 8 (9%) | 34 (45%) |
| Standard prophylactic DLI | – | 42 (55%) |
| BM chimerism at time of first DLI | ||
| FDC | 28 (33%) | 25 (34%) |
| Low MC (1-4% mixed chimerism) | 32 (38%) | 30 (41%) |
| High MC (≥5% mixed chimerism) | 24 (29%) | 19 (26%) |
| Unknown | 4 | 2 |
| ALC at time of first DLI (x106/l) | ||
| ≥1000 | 41 (47%) | 45 (61%) |
| 500-999 | 29 (33%) | 20 (27%) |
| <500 | 17 (20%) | 9 (12%) |
| Unknown | 1 | 2 |
*One patient had not received a second consolidation course before transplant and received 2 days cyclophosphamide 750 mg/m2 intravenously additionally to the conditioning regimen.
Characteristics are given at time of alloSCT unless otherwise indicated.
DLI, donor lymphocyte infusion; alloSCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; Cyclo, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; Flu, fludarabine; Ara-C, cytarabine; Amsa, amsacrine; RD, related donor; UD, unrelated donor; G-CSF, granulocyte-colony stimulation factor; PBSC, peripheral blood stem cells; BM, bone marrow; CMV, cytomegalovirus; EBV, Epstein-Barr virus; CR, complete morphological remission; CMML, chronic myelomonocytic leukemia; MRD, minimal residual disease; MC, mixed chimerism; FDC, full donor chimerism; ALC, absolute lymphocyte count.